New blood test could spot six gut cancers before symptoms start
NCT ID NCT07224750
First seen Nov 05, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study is developing a blood test that looks for tiny genetic molecules called miRNAs, which can signal the presence of several gastrointestinal cancers like liver, pancreatic, and colorectal cancer. Researchers will analyze blood samples from 1,000 adults—half with cancer and half without—to see how accurately the test can distinguish between them. The goal is to create a noninvasive, affordable screening tool that could catch these cancers earlier, when they are easier to treat.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Nat Medical Ctr
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
miRNA blood test
What this could lead to
If successful, this could lead to a simple, noninvasive blood test for early detection of several gastrointestinal cancers, improving survival rates.
What could go wrong
This is an early-stage study focused on diagnostic accuracy, not treatment. The test may not be sensitive or specific enough for widespread use, and further validation is needed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.